Assessment of Oleoylethanolamide supplementation in prevention and treatment of non-alcoholic fatty liver disease
- Conditions
- on-alcoholic fatty liver disease.Fatty (change of) liver, not elsewhere classifiedK76.0
- Registration Number
- IRCT20090609002017N32
- Lead Sponsor
- Vice chancellor for research , Tabriz University of Medical Sciences, Nutrition Research Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Ages between 20 to 50 years
body mass index (BMI) 30 to 40 kg/m2
Diagnosis of non-alcoholic fatty liver disease by a liver specialist based on ultrasound
Regular use of nonsteroidal anti-inflammatory agents (NSAIDs) and antibiotics
Use of hepatotoxic drugs such as phenytoin, amiodarone, levothyroxine, amoxifene, lithium
Use of antihypertensive drugs
Using weight loss and lipid-lowering drugs
Use of probiotic and prebiotic supplements; vitamins; minerals; antioxidants; and omega 3 supplements in the last 3 months
Smoking
Pregnancy
Breast-feeding
Menopause
Pathological conditions affecting the liver such as viral hepatitis, acute or chronic hepatic impairment, liver transplantation, acute systemic disease
Gastrointestinal diseases
Diabetes
Heart failure
Thyroid disorders
Kidney Diseases
Haemochromatosis
Wilson's disease
Alpha-1 antitrypsin deficiency
Autoimmune diseases
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method